NASDAQ:ESPR

Esperion Therapeutics Stock Insider Trading

Healthcare > Drug Manufacturers - Specialty & Generic

Buy ESPR

*Your capital is at risk

$3.14

+0 (+0%)

At Close: Jun 03, 2026

Esperion Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 39.77. In total, the insiders bought 10.51M and sold 314.74K ESPR shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	39.77
● Buy	10.51M shares
● Sell	314.74K shares
62% Buy Activity Negligible or No Correlation
Buy Signal Medium Confidence Mar 13, 2026 Analysis Breakdown: Supported by a positive Insider Power Score of 39.77. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 18, 2025 Sell	Common Stock S-Sale	Koenig Sheldon L. President And CEO	CEO / President	13 047 Value: $19.6K
Mar 18, 2025 Sell	Common Stock S-Sale	Koenig Sheldon L. President And CEO	CEO / President	13 047 Value: $19.6K
Mar 18, 2025 Sell	Common Stock S-Sale	Warren Eric Chief Commercial Officer	Officer	2 433 Value: $4K
Mar 18, 2025 Sell	Common Stock S-Sale	Halladay Benjamin Chief Financial Officer	C-Suite Officer	3 535 Value: $5K
Mar 14, 2025 Buy	Common Stock A-Award	Koenig Sheldon L. President And CEO	CEO / President	840 000 Value: $1.26M
Mar 14, 2025 Buy	Stock Option (right to buy A-Award	Koenig Sheldon L. President And CEO	CEO / President	753 000 Value: $1.13M
Mar 14, 2025 Buy	Common Stock A-Award	Halladay Benjamin Chief Financial Officer	C-Suite Officer	238 000 Value: $357.0K
Mar 14, 2025 Buy	Stock Option (right to buy) A-Award	Halladay Benjamin Chief Financial Officer	C-Suite Officer	213 000 Value: $319.5K
Mar 14, 2025 Buy	Common Stock A-Award	Warren Eric Chief Commercial Officer	Officer	213 000 Value: $319.5K
Mar 14, 2025 Buy	Stock Option (right to buy) A-Award	Warren Eric Chief Commercial Officer	Officer	191 000 Value: $286.5K
Mar 14, 2025 Buy	Common Stock A-Award	Looker Benjamin General Counsel	Officer	224 000 Value: $336.0K
Mar 14, 2025 Buy	Stock Option (right to buy) A-Award	Looker Benjamin General Counsel	Officer	201 000 Value: $301.5K
Mar 14, 2025 Buy	Stock Option (right to buy) A-Award	Warren Eric Chief Commercial Officer	Officer	191 000 Value: $286.5K
Mar 14, 2025 Buy	Stock Option (right to buy) A-Award	Looker Benjamin General Counsel	Officer	201 000 Value: $301.5K
Mar 14, 2025 Buy	Common Stock A-Award	Looker Benjamin General Counsel	Officer	224 000 Value: $336.0K
Mar 14, 2025 Buy	Common Stock A-Award	Warren Eric Chief Commercial Officer	Officer	213 000 Value: $319.5K
Mar 14, 2025 Buy	Stock Option (right to buy) A-Award	Halladay Benjamin Chief Financial Officer	C-Suite Officer	213 000 Value: $319.5K
Mar 14, 2025 Buy	Common Stock A-Award	Halladay Benjamin Chief Financial Officer	C-Suite Officer	238 000 Value: $357.0K
Mar 14, 2025 Buy	Stock Option (right to buy A-Award	Koenig Sheldon L. President And CEO	CEO / President	753 000 Value: $1.13M
Mar 14, 2025 Buy	Common Stock A-Award	Koenig Sheldon L. President And CEO	CEO / President	840 000 Value: $1.26M
Feb 19, 2025 Sell	Common Stock S-Sale	Warren Eric Chief Commercial Officer	Officer	239 Value: $446
Feb 19, 2025 Sell	Common Stock S-Sale	Halladay Benjamin Chief Financial Officer	C-Suite Officer	11 Value: $20
Feb 19, 2025 Sell	Common Stock S-Sale	Halladay Benjamin Chief Financial Officer	C-Suite Officer	11 Value: $20
Feb 19, 2025 Sell	Common Stock S-Sale	Warren Eric Chief Commercial Officer	Officer	239 Value: $446
Jan 17, 2025 Sell	Common Stock S-Sale	Warren Eric Chief Commercial Officer	Officer	123 Value: $278

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ESPERION THERAPEUTICS

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration a...

Read Full Profile Here